Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

MNOV

Live52w low +18.2%

Annual Quarterly

Core line items from MNOV's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: MEDICINOVA, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-11	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$44.20K	$186.98K	$409.66K	$257.92K	$134.60K
Operating Income	Not available	$-2.84M	$-13.28M	$-10.19M	$-6.81M
Net Income	Not available	$-2.59M	$-12.00M	$-9.20M	$-3.28M
EPS (Diluted)	$-0.07	$-0.05	$-0.24	$-0.19	$-0.13
Total Assets	Not available	$42.70M	$45.60M	$47.58M	$49.82M
Total Liabilities	Not available	$3.30M	$4.02M	$3.61M	$2.97M
Cash & Equivalents	Not available	$27.33M	$30.81M	$32.56M	$34.26M
Free Cash Flow OCF − CapEx	Not available	$-3.48M	$-9.81M	$-7.80M	Not available
Shares Outstanding	Not available	49.22M	49.22M	49.05M	49.05M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from MNOV's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +18.2%

Entity: MEDICINOVA, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-11	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$44.20K	$186.98K	$409.66K	$257.92K	$134.60K
Operating Income	Not available	$-2.84M	$-13.28M	$-10.19M	$-6.81M
Net Income	Not available	$-2.59M	$-12.00M	$-9.20M	$-3.28M
EPS (Diluted)	$-0.07	$-0.05	$-0.24	$-0.19	$-0.13
Total Assets	Not available	$42.70M	$45.60M	$47.58M	$49.82M
Total Liabilities	Not available	$3.30M	$4.02M	$3.61M	$2.97M
Cash & Equivalents	Not available	$27.33M	$30.81M	$32.56M	$34.26M
Free Cash Flow OCF − CapEx	Not available	$-3.48M	$-9.81M	$-7.80M	Not available
Shares Outstanding	Not available	49.22M	49.22M	49.05M	49.05M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.